跳至主要内容
临床试验/NCT02781779
NCT02781779已完成不适用

Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG Dressing Post Cardiac Device Implant

Kansas City Heart Rhythm Institute1 个研究点 分布在 1 个国家目标入组 147 人开始时间: 2016年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
147
试验地点
1
主要终点
Pocket Hematoma, Moderate-Severe

研究概览

简要总结

The purpose of this study is to learn how effective each of the two dressings, Silverlon® and AQUACEL® AG, are in preventing post cardiac implantable electronic devices (CIED) procedure wound infections.

详细描述

This is a single center, prospective, 2-arm randomized, non-blinded study. A total of 100 participants will be assigned to the Silverlon arm and 100 to the AQUACEL AG arm.

The number of procedures to implant CIED has risen in recent years. With this rise has also brought a rise in post-procedure infections. Infections will happen and there is a continued need to improve all aspects of the surgery and post-operative care. Wound coverage with appropriate dressings is one aspect that needs to be studied in CIED implant patients. Silverlon and AQUACEL AG are two options of dressings available for these patients. This study will look to see if one of the two is a better option for post-operative CIED implant patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients who are scheduled for a CIED implant, generator change, or upgrade at the University of Kansas Hospital
  • •Able to give informed consent

排除标准

  • •Patients who are already on antibiotics for another reasons
  • •Immunocompromised patients such as those on immunosuppressant's and HIV positive patients
  • •Patients who are post device explant for lead infection
  • •Patients with an allergy to adhesive, silver or an allergy to the dressing(s) or their components

研究组 & 干预措施

Silverlon®

Active Comparator

Subjects randomized to this arm will receive Silverlon® dressing postoperative.

干预措施: Silverlon® (Device)

AQUACEL® AG

Active Comparator

Subjects randomized to this arm will receive AQUACEL® AG dressing postoperative.

干预措施: AQUACEL® AG (Device)

结局指标

主要结局

Pocket Hematoma, Moderate-Severe

时间窗: 7-10 days post implant

A pocket hematoma is an accumulation of blood in or near the surgical incision which occurs because of a defect in hemostasis such as injury to blood vessels. Pocket hematoma is associated with local discomfort, an increased risk of infection, and may require surgical intervention or lead to lengthier hospital stays. Mild - Ecchymosis or mild effusion in the pocket, no swelling or pain to device-pocket (watchful waiting) Moderate - Large effusion in the pocket leading to swelling and causing functional impairment or pain to device-pocket Severe - Any pocket hematoma requiring: Reoperation and/or resulting in prolongation of hospitalization (defined as extended hospitalization or rehospitalization for \>24 hours, postindex surgery, primarily due to hematoma) and/or requiring interruption of OAC (defined as reversal or intentional withholding, in response to pocket hematoma, resulting in subtherapeutic anticoagulation for \>24 hours)

次要结局

  • Rash After Removal(At time of dressing removal, up to 10 days post operative)
  • Pocket Dehiscence(At time of dressing removal, up to 10 days post operative)
  • Site Itching/Burning(At time of dressing removal, up to 10 days post operative)
  • Wound Drainage(At time of dressing removal, up to 10 days post operative)
  • Skin Erythema(At time of dressing removal, up to 10 days post operative)

研究者

发起方
Kansas City Heart Rhythm Institute
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验